Literature DB >> 25846576

Protection against Helicobacter pylori infection in BALB/c mice by oral administration of multi-epitope vaccine of CTB-UreI-UreB.

Jing Yang1, Lv-xia Dai2, Xing Pan3, Hongren Wang4, Bei Li5, Jie Zhu6, Ming-yuan Li4, Xin-Li Shi7, Bao-ning Wang8.   

Abstract

Chronic gastric infection by the Gram-negative bacterium Helicobacter pylori (H. pylori) is strongly associated with gastritis, gastric ulcer and the development of distal gastric carcinoma and gastric mucosal lymphoma in humans. Antibiotic treatment of H. pylori is becoming less effective because of increasing antibiotic resistance; other treatment approaches such as specifically targeted methods, etc. to destroy this organism would be beneficial. An epitope vaccine is a promising option for protection against H. pylori infection. In this study, a multi-epitope vaccine was constructed by linking cholera toxin B subunit (CTB), two antigenic fragments of H. pylori urease I subunit (UreI20-29, UreI98-107) and four antigenic fragments of H. pylori urease B subunit (UreB12-23, UreB229-251, UreB327-400, UreB515-561), resulting in the recombinant CTB-UreI-UreB (BIB). Its protective effect against H. pylori infection was evaluated in BALB/c mice. Significant protection against H. pylori challenge was achieved in BALB/c mice immunized with BIB (15/18, 83.3%), rIB plus rCTB (6/18, 33.3%) and rIB (2/18, 11.1%) separately, while no protective effect was found in the mice immunized with either adjuvant rCTB alone or PBS. The induction of significant protection against H. pylori is possibly mediated by specific serum IgA and mucosal sIgA antibodies, and a mixed Th1/Th2/Th17 cells response. This multi-epitope vaccine might be a promising vaccine candidate that helps to control H. pylori infection. © FEMS 2015. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Helicobacter pylori; cholera toxin B subunit; epitope vaccine; neutralizing antibody; urease B subunit; urease I subunit

Mesh:

Substances:

Year:  2015        PMID: 25846576     DOI: 10.1093/femspd/ftv026

Source DB:  PubMed          Journal:  Pathog Dis        ISSN: 2049-632X            Impact factor:   3.166


  6 in total

Review 1.  Treatment of Helicobacter pylori infection: Current and future insights.

Authors:  Maliheh Safavi; Reyhaneh Sabourian; Alireza Foroumadi
Journal:  World J Clin Cases       Date:  2016-01-16       Impact factor: 1.337

2.  Oral Immunization with a Multivalent Epitope-Based Vaccine, Based on NAP, Urease, HSP60, and HpaA, Provides Therapeutic Effect on H. pylori Infection in Mongolian gerbils.

Authors:  Le Guo; Hua Yang; Feng Tang; Runting Yin; Hongpeng Liu; Xiaojuan Gong; Jun Wei; Ying Zhang; Guangxian Xu; Kunmei Liu
Journal:  Front Cell Infect Microbiol       Date:  2017-08-04       Impact factor: 5.293

3.  Protein signature characterizing Helicobacter pylori strains of patients with autoimmune atrophic gastritis, duodenal ulcer and gastric cancer.

Authors:  Valli De Re; Ombretta Repetto; Stefania Zanussi; Mariateresa Casarotto; Laura Caggiari; Vincenzo Canzonieri; Renato Cannizzaro
Journal:  Infect Agent Cancer       Date:  2017-04-27       Impact factor: 2.965

4.  Status of vaccine research and development for Helicobacter pylori.

Authors:  Philip Sutton; Joanne M Boag
Journal:  Vaccine       Date:  2018-04-05       Impact factor: 3.641

5.  Protection Against Helicobacter pylori Infection in BALB/c Mouse Model by Oral Administration of Multivalent Epitope-Based Vaccine of Cholera Toxin B Subunit-HUUC.

Authors:  Xing Pan; Hong Ke; Xiaojuan Niu; Shan Li; Jun Lv; Longrui Pan
Journal:  Front Immunol       Date:  2018-05-08       Impact factor: 7.561

6.  Antigenic and conserved peptides from diverse Helicobacter pylori antigens.

Authors:  Cecília R C Calado
Journal:  Biotechnol Lett       Date:  2022-03-11       Impact factor: 2.716

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.